Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells

In contrast to class I/IIb/pan histone deacetylase inhibitors (HDACi), the role of class IIa HDACi as anti-cancer chemosensitizing agents is less well understood. Here, we studied the effects of HDAC4 in particular and the class IIa HDACi CHDI0039 on proliferation and chemosensitivity in Cal27 and c...

Full description

Bibliographic Details
Main Authors: Christian Schrenk, Lukas M. Bollmann, Corinna Haist, Arthur Bister, Constanze Wiek, Maria Wecker, Dennis Roth, Patrick Petzsch, Karl Köhrer, Alexandra Hamacher, Helmut Hanenberg, Georg Fluegen, Matthias U. Kassack
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:International Journal of Molecular Sciences
Subjects:
class IIa histone deacetylase
HDAC4
HDAC5
HDAC inhibitor
CHDI0039
bortezomib
Online Access:https://www.mdpi.com/1422-0067/24/6/5553

Internet

https://www.mdpi.com/1422-0067/24/6/5553

Similar Items